AU2022281345A1 - Substituted fused bicyclic macrocyclic compounds and related methods of treatment - Google Patents
Substituted fused bicyclic macrocyclic compounds and related methods of treatment Download PDFInfo
- Publication number
- AU2022281345A1 AU2022281345A1 AU2022281345A AU2022281345A AU2022281345A1 AU 2022281345 A1 AU2022281345 A1 AU 2022281345A1 AU 2022281345 A AU2022281345 A AU 2022281345A AU 2022281345 A AU2022281345 A AU 2022281345A AU 2022281345 A1 AU2022281345 A1 AU 2022281345A1
- Authority
- AU
- Australia
- Prior art keywords
- formula
- another embodiment
- alkyl
- alkylene
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163193243P | 2021-05-26 | 2021-05-26 | |
| US63/193,243 | 2021-05-26 | ||
| PCT/US2022/030839 WO2022251302A1 (en) | 2021-05-26 | 2022-05-25 | Substituted fused bicyclic macrocyclic compounds and related methods of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022281345A1 true AU2022281345A1 (en) | 2023-11-30 |
Family
ID=82851881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022281345A Pending AU2022281345A1 (en) | 2021-05-26 | 2022-05-25 | Substituted fused bicyclic macrocyclic compounds and related methods of treatment |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240182491A1 (https=) |
| EP (1) | EP4347046A1 (https=) |
| JP (1) | JP2024520395A (https=) |
| CN (1) | CN117999265A (https=) |
| AU (1) | AU2022281345A1 (https=) |
| CA (1) | CA3219506A1 (https=) |
| WO (1) | WO2022251302A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250155550A (ko) | 2023-03-16 | 2025-10-30 | 다케다 야쿠힌 고교 가부시키가이샤 | 매크로시클릭 헤테로시클 화합물 및 이의 용도 |
| US20240425521A1 (en) | 2023-06-01 | 2024-12-26 | H. Lundbeck A/S | Spiromacrocyclic orexin 2 receptor agonists |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
| WO2026017128A1 (zh) * | 2024-07-17 | 2026-01-22 | 江苏恩华药业股份有限公司 | 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途 |
| WO2026064378A1 (en) * | 2024-09-18 | 2026-03-26 | Vertex Pharmaceuticals Incorporated | Macrocyclic sulfonamide modulators |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8258163B2 (en) | 2008-06-04 | 2012-09-04 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
| WO2014198880A1 (en) | 2013-06-14 | 2014-12-18 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
| US20160250224A1 (en) | 2013-09-24 | 2016-09-01 | The Board Of Regents Of The University Of Texas System | Orexin-control of bone formation and loss |
| CA2930693A1 (en) | 2013-11-15 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Methods of treating heart failure with agonists of hypocretin receptor 2 |
| PE20161064A1 (es) | 2013-12-12 | 2016-10-28 | Univ Tsukuba | Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo |
| WO2015147240A1 (ja) | 2014-03-28 | 2015-10-01 | 国立大学法人筑波大学 | 敗血症の予防治療剤 |
| PL3411358T3 (pl) | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
| WO2018053302A1 (en) * | 2016-09-19 | 2018-03-22 | Ensemble Therapeutics Corporation | Macrocyclic compounds for the inhibition of indoleamine-2,3-dioxygenase activity and use thereof |
| US20200039998A1 (en) * | 2016-12-19 | 2020-02-06 | Epizyme, Inc. | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof |
| US20200207734A1 (en) | 2017-08-03 | 2020-07-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US11319286B2 (en) * | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| CN110156813B (zh) * | 2018-02-13 | 2023-07-25 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| CN110627812B (zh) * | 2018-06-25 | 2022-10-11 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| US12077522B2 (en) * | 2018-06-29 | 2024-09-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| US11098029B2 (en) * | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| FI4065585T3 (fi) * | 2019-11-25 | 2025-09-26 | Alkermes Inc | Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä |
| WO2022109117A1 (en) * | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | 3-amino pyrrolidine and piperidine macrocyclic orexin receptor agonists |
| US12006330B2 (en) * | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
-
2022
- 2022-05-25 EP EP22754192.7A patent/EP4347046A1/en active Pending
- 2022-05-25 WO PCT/US2022/030839 patent/WO2022251302A1/en not_active Ceased
- 2022-05-25 JP JP2023572622A patent/JP2024520395A/ja active Pending
- 2022-05-25 AU AU2022281345A patent/AU2022281345A1/en active Pending
- 2022-05-25 CN CN202280047653.8A patent/CN117999265A/zh active Pending
- 2022-05-25 CA CA3219506A patent/CA3219506A1/en active Pending
-
2023
- 2023-11-14 US US18/389,260 patent/US20240182491A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240182491A1 (en) | 2024-06-06 |
| CN117999265A (zh) | 2024-05-07 |
| WO2022251302A1 (en) | 2022-12-01 |
| JP2024520395A (ja) | 2024-05-24 |
| CA3219506A1 (en) | 2022-12-01 |
| EP4347046A1 (en) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4347046A1 (en) | Substituted fused bicyclic macrocyclic compounds and related methods of treatment | |
| EP4329877B1 (en) | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity | |
| JP7846113B2 (ja) | 置換ピペリジノ化合物及び関連する治療方法 | |
| EP4347604B1 (en) | Substituted carbamate macrocyclic compounds and related methods of treatment | |
| US20250223260A1 (en) | Substituted Pyrrolidinyl And Piperidinyl Compounds And Related Methods Of Treatment | |
| US20250230141A1 (en) | Substituted Fused Bicyclic Compounds and Related Methods of Treatment | |
| US20250223276A1 (en) | Substituted Pyrrolidinyl And Piperidinyl Compounds And Related Methods Of Treatment | |
| HK40099265B (en) | Substituted piperidino compounds and related methods of treatment | |
| HK40099265A (en) | Substituted piperidino compounds and related methods of treatment |